SKA2 Methylation Biomarker for PTSD Risk Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective biomarkers for predicting Post-Traumatic Stress Disorder (PTSD), which is a significant issue affecting a substantial portion of military personnel and civilians, leading to increased medical and social costs and impaired quality of life.
Innovation Solution
The development of a biomarker based on DNA methylation status and genotype, specifically at the SKA2 gene's CpG site, to predict PTSD risk by measuring DNA methylation levels and genotype at rs7208505, utilizing a linear model that incorporates age, sex, and stress/anxiety metrics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods are used for predicting PTSD, then no effective biomarkers are available, but this leads to inability to predict PTSD risk accurately
Solution Approach 1:
The patent changes the parameters being measured from conventional clinical assessments to specific molecular parameters (DNA methylation levels at SKA2 gene CpG sites and rs7208505 genotype). This parameter transformation enables objective, quantifiable biomarker measurement that achieves 78% accuracy in predicting PTSD development, directly resolving the contradiction between measurement precision and reliability.
2Measurement precision
If DNA methylation and genotype biomarkers are used, then PTSD prediction accuracy improves to 78%, but the complexity of the testing method increases
Solution Approach 1:
The patent extracts specific, discrete molecular markers (SKA2 gene methylation at particular CpG sites and rs7208505 SNP) from the complex genome. By focusing on only these specific extracted targets rather than analyzing the entire genome or multiple genes, the method achieves high predictive accuracy while maintaining relatively simple and cost-effective laboratory procedures.
Data Source
AI summary
The present invention relates to the field of biomarkers. More specifically, the present invention relates to the use of biomarkers to predict post-traumatic stress disorder (PTSD). In one embodiment, a method for predicting PTSD in a subject comprises the steps of (a) measuring the DNA methylation level of a CpG dinucleotide in the 3′ untranslated region of SKA2; (b) identifying the genotype at a SNP within the 3′ UTR of SKA2, and (c) predicting PTSD in the subject using a prediction algorithm.